Nanoparticle-based drug delivery systems: Promising approaches against infections

Brazilian Archives of Biology and Technology

Volumn 57, Issue 2, 2014, Pages 209-222

  Ranghar, Shweta ^a   Sirohi, Parul ^a   Verma, Pritam ^a   Agarwal, Vishnu ^a  

^a MOTILAL NEHRU NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Antimicrobial nanoparticles; Drug delivery system; Drug resistance; Infection; Metal and metal oxide; Review

Indexed keywords

EID: 84898630871     PISSN: 15168913     EISSN: 16784324     Source Type: Journal    
DOI: 10.1590/S1516-89132013005000011     Document Type: Article

References (83)

1. Abeylath SC, Turos E, Dickey S, Lim DV. Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis. Bioorg Med Chem. 2008; 16: 2412-2418.
2. Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006; 48: 171-176.
3. Bala T, Armstrong G, Laffir F, Thornton R. Titaniasilver and alumina-silver composite nanoparticles: Novel, versatile synthesis, reaction mechanism and potential antimicrobial application. Adv Colloid Interface Sci. 2011; 356: 395-403.
4. Balogh L, Swanson DR, Tomalia DA, Hagnauer GL, McManus AT. Dendrimer-Silver Complexes and Nanocomposites as Antimicrobial Agents. Nano Lett. 2001; 1: 18-21.
5. Beaulac C, Clement-Major S, Hawari J, Legace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother. 1996; 40: 665-669.
6. Berkowitz FE. Antibiotic resistance in bacteria. South Med J. 1995; 88 (8): 797-804.
7. Berlin JM, Leonard AD, Pham TT, Sano D, Marcano DC, Yan S. Effective Drug Delivery, in vitro and in vivo, by Carbon-Based Nanovectors Non-Covalently Loaded With Unmodified Paclitaxel. ACS Nano. 2010; 4(8): 4621-4636.
8. Bhadra D, Bhadra S and Jain NK. PEGylated peptide based dendritic nanoparticulate systems for delivery of artemether. J Drug Del Sci Tech. 2005; 15: 65-73.
9. Bhuleier E, Wehner W, Vogtle F. "Cascade"- and "nonskid-chain-like" syntheses of molecular cavity topologies. Synthesis. 1978; 155-158.
10. Cao Y, Gu Y, Ma H, Bai J, Liu L, Zhao P. Selfassembled nanoparticle drug delivery systems from galactosylated polysaccharide-doxorubicin conjugate loaded doxorubicin. Int J Biol Macromol. 2010; 46: 245-249.
11. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002; 238: 241-245.
12. Chakraborty SP, Sahu SK, Mahapatra SK, Susmita S, Bal M, Roy S. Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents. Nanotechnology. 2010; 21: 1-9.
13. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009; 30: 1627-1634.
14. Cheng Y, Qu H, Ma M, Xu Z, Xu P, Fang Y. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. Eur J Med Chem. 2007; 42: 1032- 1038.
15. Choi JY, Kim KH, Choy KC, Oh KT, Kim KN. Photocatalytic antibacterial effect of TiO2 film formed on Ti and TiAg exposed to Lactobacillus acidophilus. J Biomed Materials Res B App Biomaterials. 2007; 80: 353-359.
16. Chopra I. The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J Antimicro Chemother. 2007; 59(4): 587-590.
17. Chung YC, Wang HL, Chen YM, Li SL. Effect of abiotic factors on the antibacterial activity of chitosan against waterborne pathogens. Bioresour Technol. 2003; 82: 179-184.
18. Cohen ML. Changing patterns of infectious disease. Nature. 2000; 406: 762-767.
19. Devarakonda B, Hill RA, Liebenberg W, Brits M, Villiers MM. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm. 2005; 304: 193-209.
20. Espuelas MS, Legrand P, Campanero MA, Appel M, Cheron M, Gamazo C. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother. 2003; 52: 419-427.
21. Esteban TL, Malpartida F, Esteban CA, Pecharromán C, Moya JS. Antibacterial and antifungal activity of a soda-lime glass containing copper nanoparticles. Nanotechnology. 2009; 20(50): 505-701.
22. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol. 2004; 2: 820-832.
23. Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan, PT, Venketesan R. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: A study against gram-positive and gramnegative bacteria. Nanomed Nanotech Biol Med. 2010; 6: 103-109.
24. Fayaz AM, Girilal M, Mahdy SA, Somsundar SS, Venkatesan R, Kalaichelvan PT. Vancomycin bound biogenic gold nanoparticles: a different perspective for development of anti VRSA agents. Process Biochem. 2011; 46(3): 636-641.
25. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5: 161-171.
26. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005; 10: 35-43.
27. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med. 1996; 335: 1445-1453.
28. Gordon T, Perlstein B, Houbara O, Felner I, Banin E, Margel S. Synthesis and characterization of zinc/iron oxide composite nanoparticles and their antibacterial properties. Colloids Surf A. 2011; 374:1-8.
29. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J Mater Chem. 2011; 21: 5845- 5855.
30. Hetrick EM, Shin JK, Paul HS, Schoenfisch MH. Antibiofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials. 2009; 30(14): 2782- 2789.
31. Honary S, Ghajar K, Khazaeli P, Shalchian P. Preparation, characterization and antibacterial properties of silver-chitosan nanocomposites using different molecular weight grades of chitosan. Trop J Pharma Res. 2011; 10: 69-74.
32. Jain KK. Applications of nanobiotechnology in clinical diagnostics. Clin Chem. 2007; 53(11): 2002-2009.
33. Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target. 2008; 16: 798-805.
34. Kuhn KP, Chaberny IF, Massholder K, Stickler M, Benz VW, Sonntag HG. Disinfection of surfaces by photocatalytic oxidation with titanium dioxide and UVA light. Chemosphere. 2003; 53: 71-77.
35. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976; 263(5580): 797-800.
36. Lara HH, Ayala-núñez NV, Ixtepan Turrent LDC, Rodríguez PC. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J Microbiol Biotechnol. 2010; 26: 615-621.
37. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001; 90: 667- 680.
38. Lili He, Yang L, Azlin M, Mengshi L. Antifungal activity of zinc oxide nanoparticles against Botrytis cinerea and Penicillium expansum. Microbiol Res. 2011;166(3): 207-215.
39. Lipovsky A, Tzitrinovich Z, Friedmann H, Applerot G, Gedanken A, Lubart R. EPR study of visible lightinduced ROS generation by nanoparticles of ZnO. J Physical Chem C. 2009;113(36):15997-16001.
40. Liu Y, He L, Mustapha A, Li H, Hu ZQ, Lin M. Antibacterial activities of zinc oxide nanoparticles against Escherichia coli. J Appl Microbiol. 2009; 107: 1193-1201.
41. Makhluf S, Dror R, Nitzan Y, Abramovich Y, Jelinek R, Gedanken A. Microwave-assisted synthesis of nanocrystalline MgO and its use as a bacteriocide. Adv Funct Mater. 2005; 15(10):1708-1715.
42. Martinez-Gutierrez F, Olive PL, Banuelos A, Orrantia E, Nino N, Sanchez EM. Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomed Nanotechnol Biol Med . 2010; 6(5): 681-688.
43. Mosqueira VC, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium bergheiinfected mice. Antimicrob Agents Chemother. 2004; 48: 1222-1228.
44. Muranyi P, Schraml C, Wunderlich J. Antimicrobial efficiency of titanium dioxide-coated surfaces. J Appl Microbiol. 2010; 108(6): 1966-1973.
45. Nanjwadea BK, Bechraa HM, Derkara GK, Manvia FV, Nanjwadeb VK. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009; 38: 185-196.
46. Niemeyer CM. Nanoparticles, proteins and nucleic acids: biotechnology meets material science. Angew Chem Int Ed. 2001;40 (22): 4128-4158.
47. Omri A, Suntres ZE, Shek PN. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol. 2002; 64: 1407-1413.
48. Pandey R, Khuller G K. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother. 2006; 57: 1146-1152.
49. Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res . 2004; 339: 2693-2700.
50. Rabea EI, Badawy ME, Stevens CV, Smagghe G, Steurbaut W. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules. 2003; 6: 1457-1465.
51. Raghupathi KR, Koodali RT, Manna AC. Sizedependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles. Langmuir. 2011; 27(7): 4020-4028.
52. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009; 27:76-83.
53. Reddy KM, Feris K, Bell J, Wingett DG, Hanley C, Punnoose A. Selective toxicity of zinc oxide nanoparticles to prokaryotic and eukaryotic systems. Appl Phys Lett. 2007; 90 (213902): 2139021- 2139023.
54. Ren G, Hu D, Cheng EW, Vargas-Reus MA, Reip P, Allaker RP. Characterisation of copper oxide nanoparticles for antimicrobial applications. Int J Antimicrob Agents. 2009; 33(6):587-590.
55. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010; 13(1): 106-112
56. Ruparelia JP, Chatterijee AK, Duttagupta SP, Mukherji S. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater. 2008; 4: 707-716.
57. Sadiq IM, Chowdhury B, Chandrasekaran N, Mukherjee A, Antimicrobial sensitivity of Escherichia coli to alumina nanoparticles. Nanomed Nanotechnol Biol Med. 2009; 5: 282-286.
58. Sajja HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol. 2009; 6 (1): 43-51.
59. Sanna V, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol. 2007; 59: 1057-1064.
60. Schiffelers R, Storm G, Bakker-Woudenberg I. Liposome encapsulated aminoglycosides in preclinical and clinical studies. J Antimicrob Chemother. 2001; 48: 333-344.
61. Shah LK, Amiji MM. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res. 2006; 23: 2638-2645.
62. Sinha N, Yeow JTW. Carbon nanotubes for biomedical applications. IEEE Trans Nanobiosci. 2005; 4(2):180-195.
63. Souto EB, Muller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul. 2005; 22: 501-510.
64. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004; 278: 71-77.
65. Sundaram R, Ramasamy G, Kasi S, Samayanan S. Antibacterial activity of metal oxide nanoparticles against ophthalmic pathogens. Int J Pharmaceutical Res Dev. 2011; 3 (5) / Article No - 21.
66. Takemoto K, Yamamoto Y, Ueda Y, Sumita Y, Yoshida K, Niki Y. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother. 2004; 53: 311-317.
67. Talyor PW, Stapleton PD, Luzio JP. New ways to treat bacterial infections. Drug Discov Today. 2002; 7 (21): 1086-1091.
68. Taubes G. The bacteria fight back. Science. 2008; 321: 356-361.
69. Touati D. Iron and oxidative stress in bacteria. Arch Biochem Biophys. 2000; 373(1):1-6.
70. Tran N, Mir A, Mallik D, Sinha A, Nayar S, Webster TJ. Bactericidal effect of iron oxide nanoparticles on Staphylococcus aureus. Int J Nanomedicine. 2010; 5: 277 - 283.
71. Turos E, Shim JY, Wang Y, Greenhalgh K, Reddy GS, Dickey S, Lim DV. Antibiotic-conjugated polyacrylate nanoparticles: new opportunities for development of anti-MRSA agents. Bioorg Med Chem Lett. 2007; 17: 53-56.
72. Tyagi R, Lala S, Verma AK, Nandy AK, Mahato SB, Maitra A, Basu MK. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Target. 2005; 13: 161-171.
73. Umamaheshwari RB, Jain NK. Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target. 2003; 11: 415-423.
74. Urban-Morlan Z, Ganem-Rondero A, Melgoza- Contreras LM, Escobar-havez JJ, Nava-Arzaluz MG, Quintanar-Guerrero D. Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsificationdiffusion method. Int J Nanomedicine. 2010; 5: 611- 620.
75. Walker CB. Selected antimicrobial agents: mechanisms of action, side effects and drug interactions. Periodontol 2000. 1996; 10: 12-28.
76. Wang Z, Lee YH, Wu B, Horst A, Kang Y, Tang YJ, Chen DR. Anti-microbial activities of aerosolized transition metal oxide nanoparticles. Chemosphere. 2010; 80: 525-529.
77. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis. 1999; 5(3): 346-352.
78. Weir E, Lawlor A, Whelan A, Regan F. The use of nanoparticles in anti-microbial materials and their characterization. Analyst. 2008; 133: 835-845.
79. Weller RB. Nitric oxide-containing nanoparticles as an antimicrobial agents and enhancer of wound healing. J Invest Dermatol. 2009; 129: 2335-2337.
80. Wong MS, Sun DS, Chang HH. Bactericidal Performance of Visible-Light Responsive Titania Photocatalyst with Silver Nanostructures. PLoS ONE. 2010; 5(4): e10394.
81. Xie Y, Shi X, He Y, Irwin PL, Jin T. Antibacterial activity and mechanism of action of zinc oxide nanoparticles against Campylobacter jejuni. App Environmental Microbiol. 2011; 77: 2325-2331.
82. Yang J. Hollow silica nanocontainers as drug delivery vehicles. Langmuir. 2008; 24: 3417-3421.
83. Zhang L, Pornpattananangkul D, Hu CMJ, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010; 17: 585-594.